Xvivo Perfusion AB Overview
Pro stress-test →Founded in 1998, XVIVO is the only MedTech company dedicated to extending the life of all major organs. The company offers machine perfusion technologies for kidneys, livers, and lungs, a solution for cold static storage of lungs, as well as organ recovery and perfusion services. XVIVO is trusted by more than 90% of all transplantation clinics, and the standard treatment in lung transplants.
Strategic Profile
Pro stress-test →In lung transplantation, XVIVO markets PERFADEX Plus for cold preservation and XPS with STEEN Solution for machine perfusion, where it is the global leader. For liver transplantation, XVIVO markets Liver Assist, the leading perfusion technology in Europe. XVIVO aims to be the fastest growing company in kidney perfusion.
Competitive Landscape
Pro stress-test →Boston Scientific, ResMed, Medtronic, Avinger, and Angiodynamics are competitors in the broader medical device space, though XVIVO's specialized focus on organ preservation gives it a niche market advantage with limited direct competition in its core segments. The company's market dominance in lung preservation (90% market share) and leadership in liver perfusion create high barriers to entry.
Industry Context
Xvivo Perfusion AB operates in Medical Technology - Organ Transplant Preservation & Perfusion Systems.
Key facts
Founded: 1998 · Headquarters: Mölndal, Sweden · Employees: 200 · Revenue: $79.9M · Market cap: $579M